Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:
BioPharmaceutical

Memory, Roche Rewrite Deal To Support Phase IIa Trial In Schizophrenia Cognitive Impairment Treatment

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Roche agrees to extra milestone payment for nicotinic alpha-7 agonist MEM 3454, but relinquishes rights to PDE4 inhibitor program.

You may also be interested in...



Roche Licenses Memory’s Lead CNS Compound

Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.

Roche Licenses Memory’s Lead CNS Compound

Swiss firm exercises option on nicotinic alpha-7 receptor agonist, gives Memory needed cash infusion.

Memory, Roche Widen Deal To Try Nicotinic Alpha-7 Agonist In Schizophrenia

MEM 3454 already known to boost cognition in Alzheimer’s patients.

Table

View full table

Related Content

Pink Sheet
Pink Sheet

Topics

Tags:
BioPharmaceutical
Latest Headlines

China’s Public Payer Wants To Define Innovative Drugs As Those With ‘Novel Benefits’

Change Is Constant For Pneumococcal Vaccines: US CDC Prepares For Merck’s V116

Woodcock Takes On Rare Disease Challenges In Retirement, Keeps FDA, Industry At Arm’s Length

German HTA Queries Polivy Benefits Amid Lack Of Evidence

See All
UsernamePublicRestriction

Register

PS066207

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By